雷公藤甲素对人子宫内膜癌细胞株HEC-1B的影响

目的:研究雷公藤甲素对人子宫内膜癌细胞株HEC-1B体外生长特性的影响。方法:观察雷公藤甲素作用后子宫内膜癌细胞株HEC-1B的生长情况;用MTT法检测雷公藤甲素抑制细胞增殖的作用;流式细胞仪观察雷公藤甲素作用后对细胞周期及凋亡的影响。结果:倒置相差显微镜下示雷公藤甲素作用后细胞生长明显受到抑制;MTT检测显示雷公藤甲素能抑制HEC-1B细胞生长且生长抑制作用呈剂量-时间依赖性;流式细胞仪检测示雷公藤甲素低浓度(5ng/ml)条件下,能诱导HEC-1B细胞发生细胞周期阻滞,主要阻滞在S期,高浓度(40,80ng/ml)雷公藤甲素使细胞主要阻滞在G2/M期,并诱导其凋亡。结论:雷公藤甲素对子宫内膜癌细胞株HEC-1B的生长有抑制作用,使其阻滞在S期和G2/M期,并诱导其凋亡。     

三苯氧胺对人子宫内膜癌细胞系Ishikawa细胞增殖的影响

目的:探讨三苯氧胺(TAM)在体外对Ishikawa人子宫内膜癌细胞株增殖的影响及其作用机制。方法:采用MTT法观察不同浓度TAM作用不同时间对Ishikawa细胞增殖的影响,另应用MTT法、流式细胞术、免疫细胞化学方法观察比较TAM、17β-雌二醇(17β-E2)及两者联合作用不同时间后对Ishikawa细胞增殖率,细胞周期时相分布以及C-myc、bcl-2、Bax 3种蛋白表达的影响。结果:TAM对Ishikawa细胞的促增殖作用在一定剂量范围内有浓度依赖性,可使G0/G1期细胞比例下降,S期细胞比例升高;C-myc、bcl-2蛋白表达增加,Bax蛋白表达下降。结论:体外TAM可能通过调节细胞周期时相分布及上调C-myc蛋白、bcl-2蛋白,下调Bax蛋白表达,促进Ishikawa人子宫内膜癌细胞增殖。     

顺铂对人子宫内膜癌RL-952细胞系Matriptase,uPA-mRNA表达的影响

目的探讨顺铂对人子宫内膜癌RL-952细胞系Matriptase,uPA-mRNA表达的影响。方法体外培养人子宫内膜癌RL-952细胞,采用反转录聚合酶链反应(RT-PCR)检测顺铂对人子宫内膜癌RL-952细胞Matriptase,uPA-mRNA表达的影响。结果 Matriptase,uPA-mRNA在人子宫内膜癌RL-952细胞系呈阳性表达。顺铂可下调Matriptase,uPA-mRNA在人子宫内膜癌RL-952细胞系的表达,具有浓度依赖性。8mg/L顺铂溶液作用不同时间后,4h后RL-952细胞Matriptase-mRNA表达量即明显下降(P0.05),而uPA-mRNA表达量于作用8h后才开始下降(P0.05),具有时间依赖性。结论顺铂可抑制人子宫内膜癌RL-952细胞系Matriptase,uPA-mRNA的表达,并具有浓度依赖性。8 mg/L的顺铂作用于人子宫内膜癌RL-952细胞后,Matriptase-mRNA比uPA-mRNA更早出现表达下调的变化。     

细胞周期素D1和p53蛋白在人子宫内膜癌共同异常表达

在正常细胞周期中,肿瘤抑制基因产物p53和细胞周期素D1有协同作用。如果这种协同作用异常就可导致细胞的恶变。许多人类癌瘤中已确定突变型p53蛋白的过度表达。为探讨周期素D1在子宫内膜癌发生中的作用,对58例正常子宫内膜和74例子宫内膜癌进行研究。据FIGO分期和分级,其中Ⅰ期51例,Ⅱ期8例,Ⅲ期15例,内有G1 39例,G2 23例,G3 12例。所有标本均用10％磷酸盐缓冲的     

VPA、SAHA和DAC对子宫内膜癌细胞系抑制作用的研究

目的:观察丙戊酸(VPA)、软木酰苯胺氧肟酸(SAHA)和5-氮-2-脱氧胞苷(DAC)对子宫内膜癌细胞RL-952和HEC-1-B的增殖抑制作用,及对细胞周期、凋亡情况和上皮型钙黏素(E-cad)基因表达的影响.方法:以VPA、SAHA和DAC作用于子宫内膜癌细胞,应用噻唑蓝(MTr)比色法、流式细胞仪和透射电镜对细胞增殖、周期和凋亡情况进行观察.应用逆转录-聚合酶链反应(RT-PCR)法观察药物作用后细胞内E-cad mRNA表达的情况.结果:VPA、SAHA和DAC作用HEC-1-B和RL-952细胞,随着药物浓度的增加,增殖抑制率明显增加(6.77％～93.25％和3.24％～89.25％,5.61％ ～97.36％和2.56％～87.85％,8.25％～92.54％和5.56％～93.47％)(P＜0.01);同一浓度药物随着作用时间的延长(24～96小时)对HEC-1-B和RL-952细胞增殖抑制率明显增加(42.41％～82.74％和36.17％ ～71.05％,43.15％～82.09％和40.38％～85.93％,43.26％～91.44％和37.75％ ～ 85.37％)(P＜0.01).HEC-1-B和RL-952细胞G0/G1期所占比例,经VPA、SAHA、DAC作用24小时后均较对照组增高,差异有高度统计学意义(P＜0.01).应用VPA、SAHA和DAC后细胞凋亡发生率均较对照组增高,差异有高度统计学意义(P＜0.01),出现特征性凋亡形态特征.VPA、SAHA和DAC作用后,RL-952和HEC-1-B细胞E-cad mRNA表达上调,较对照组均增加,差异有统计学意义(P＜0.05).结论:VPA、SAHA和DAC可有效抑制子宫内膜癌RL-952和HEC-1-B细胞增殖,有明显的细胞周期阻滞和诱导凋亡作用,对E-cad基因具有明显上调作用.     

慢病毒介导叉头框转录因子F2过表达抑制子宫内膜癌RL95-2细胞增殖与迁移

目的:探讨慢病毒介导叉头框转录因子F2(FoxF2)过表达对子宫内膜癌RL95-2细胞增殖与迁移的影响。方法:将体外培养的RL95-2细胞随机分为3组:Control、Lv-NC组和Lv-expFoxF2组。分别采用FoxF2过表达的慢病毒颗粒(Lv-expFoxF2组)和空载体对照慢病毒颗粒(Lv-NC组)感染RL95-2细胞,检测各组细胞FoxF2的mRNA和蛋白表达水平和各组细胞的增殖活性、细胞周期及体外迁移能力。结果:与Control组比较,Lv-expFoxF2组RL95-2细胞中FoxF2 mRNA和蛋白表达水平显著上调(P0.001)。与Control组比较,Lv-expFoxF2组的细胞存活率显著降低(P0.05),G_0/G_1期细胞百分比明显增加,S期细胞百分比明显减少(P0.05),体外迁移细胞数显著降低(P0.05)。结论:慢病毒介导的FoxF2过表达可抑制子宫内膜癌RL95-2细胞的增殖和迁移,诱导细胞发生G_0/G_1期阻滞。     

NS-398与前列腺素E_2对子宫内膜异位症子宫内膜细胞环氧合酶-2mRNA表达与凋亡的影响

目的 :探讨选择性环氧合酶 2 (COX- 2 )抑制剂NS -398与前列腺素E(PGE2 )对子宫内膜异位症患者子宫内膜细胞COX -2mRNA表达与细胞凋亡的影响。方法 :以体外培养的子宫内膜细胞为研究对象 ,分别用NS- 398与PGE2 处理。采用RT- PCR法、MTT法、酶联免疫吸附试验 (ELISA)和流式细胞术 ,检测刺激前后COX -2mRNA表达量、细胞增殖、凋亡与细胞周期分布情况以及上清液中凋亡抑制蛋白Bcl 2与PGE2 的释放量。结果 :NS- 398以剂量与时间依赖方式抑制COX -2mRNA的表达以及PGE2 与Bcl -2的分泌 ,抑制子宫内膜细胞增殖 ,诱导细胞凋亡 ,改变细胞周期分布 ,增加G0 /G1期细胞的比例。PGE2以时间与剂量依赖方式刺激子宫内膜细胞的COX- 2mRNA的表达 ,使Bcl- 2释放增加。同时 ,PGE2 可以逆转NS- 398对子宫内膜细胞的抑制作用 ,细胞增殖重新活跃 ,改变细胞周期分布 ,减少G0 /G1期细胞的比例 ,抑制细胞凋亡。结论 :COX- 2选择性抑制剂NS- 398,促进细胞凋亡 ,抑制细胞增殖 ,其机制可能与抑制COX -2的表达 ,降低PGE2 以及Bcl- 2释放 ,和改变细胞周期有关。PGE2 在体外能够刺激子宫内膜细胞COX- 2的表达升高 ,促进细胞增殖 ,抑制细胞凋亡。     

溶血磷脂酸对子宫内膜癌RL-952细胞尿激酶型纤溶酶原激活剂分泌的影响

目的探讨溶血磷脂酸（lysophosphatidic acid,LPA）对子宫内膜癌RL-952细胞尿激酶型纤溶酶原激活剂（urokinase-type plasminogen activator,uPA）分泌的影响。方法不同浓度的LPA刺激子宫内膜癌RL-952细胞24h,80μmol/LLPA刺激子宫内膜癌RL-952细胞不同时间后收集细胞上清液,采用酶联免疫吸附试验检测uPA的分泌情况,Transwell试验检测LPA对子宫内膜癌RL-952细胞体外迁移/侵袭能力的影响。结果 2、10μmol/L的LPA即可诱导子宫内膜癌RL-952细胞uPA的分泌增加,且随着LPA浓度的加大,uPA分泌量明显增多,二者呈明显的浓度依赖关系;80μmol/L的LPA作用于RL-952细胞时,随着时间的延长uPA分泌量增多,二者呈明显的时间依赖关系。并且LPA可以明显增加子宫内膜癌RL-952细胞的体外迁移/侵袭能力。结论 LPA可成为子宫内膜癌早期诊断及预后监测的分子标志物,并有望成为子宫内膜癌分子靶向治疗的靶标。     

17β-雌二醇对人子宫内膜癌细胞的增殖及P21ras和p-Erk表达的研究

目的:探讨17β-雌二醇(E2)对人子宫内膜腺癌雌激素受体(ER)阳性的Ishikawa和ER阴性的HEC-1A细胞增殖,细胞周期及其对丝裂原活化蛋白激酶(MAPK)通路相关蛋白P21ras和p-Erk表达的影响及意义。方法:用MTT法,流式细胞技术检测不同浓度E2作用Ishikawa和HEC-1A细胞不同时间的细胞吸光度值及细胞周期,用免疫细胞化学法检测上述细胞中P21ras和p-Erk的表达。结果:随E2浓度增加,Ishikawa细胞吸光度值上升并呈时间依赖性(P<0.01),G0～G1期比例下降(P<0.01),S期比例升高(P<0.01);HEC-1A细胞吸光度值及细胞周期无明显变化(P>0.05);10-6mol/LE2作用于Ishikawa细胞30min时,P21ras和p-Erk活化表达最强,作用于HEC-1A细胞15min时,P21ras和p-Erk即有明显表达而且达高峰,随着E2浓度增加两种细胞中P21ras和p-Erk表达均逐渐增加,呈浓度依赖性。结论:E2可促进子宫内膜癌Ishikawa细胞的增殖和周期进展,而且可以促进Ishikawa和HEC-1A中P21ras和p-Erk表达增加。     

RNA干扰抑制EZH2基因表达对子宫内膜癌细胞上皮-间质转化的影响

目的:利用RNA干扰技术靶向沉默EZH2基因,检测其对子宫内膜癌细胞增殖、迁移能力及上皮-间质转化(EMT)的影响。方法:实时荧光定量PCR、Western blot检测EZH2在子宫内膜细胞ESC及子宫内膜癌细胞株ECC-1、RL95-2中的表达差异。利用化学技术合成小分子siRNA转染子宫内膜癌细胞,靶向抑制EZH2基因表达。CCK-8、Transwell小室检测干扰前后子宫内膜癌细胞株ECC-1、RL95-2增殖、迁移能力变化。Western blot检测干扰前后子宫内膜癌细胞株ECC-1、RL95-2中EMT相关蛋白E-cadherin、α-catenin、N-cadherin和Vimentin的表达变化。结果:(1)EZH2在子宫内膜癌细胞株ECC-1、RL95-2中的表达明显高于子宫内膜细胞ESC(P0.01)。(2)RNA干扰抑制EZH2基因表达后,ECC-1、RL95-2细胞增殖、迁移能力降低(P0.01)。(3)RNA干扰抑制EZH2基因表达后,ECC-1、RL95-2细胞中上皮标志物E-cadherin和α-catenin的蛋白表达水平上调(P0.05),间质标志物N-cadherin和Vimentin的蛋白表达水平下调(P0.01)。结论:EZH2在子宫内膜癌细胞中高表达,siRNA靶向沉默EZH2基因可抑制子宫内膜癌细胞的增殖、迁移和上皮-间质转化。     

Peripheral Plasma 11 - Deoxy - 17 - Oxosteroids: Alterations during Pregnancy

The peripheral plasma levels of 17-0times0-steroids were measured serially by gas chromatography during pregnancy for 11 healthy primigravidae and compared with non-pregnancy values. Dehydroepiandrosterone sulphate and androsterone sulphate decreased markedly and progressively during pregnancy, the most rapid change being in the first trimester. Aetiocholanolone sulphate was undetectable. There was no variation in levels during the menstrual cycle. The changes in DHEA-S are consistent with the increased utilization for fetoplacental synthesis and haemodilution.     

Preimplantation Diagnosis by Fluorescence In Situ Hybridization Using 13-, 16-, 18-, 21-, 22-, X-, and Y-Chromosome Probes

Purpose: Our purpose was to select the proper chromosomes for preimplantation diagnosis based on aneuploidy distribution in abortuses and to carry out a feasibility study of preimplantation diagnosis for embryos using multiple-probe fluorescence in situ hybridization (FISH) on the selected chromosomes of biopsied blastomeres. Methods: After determining the frequency distribution of aneuploidy found in abortuses, seven chromosomes were selected for FISH probes. Blastomeres were obtained from 33 abnormal or excess embryos. The chromosome complements of both the biopsied blastomeres and the remaining sibling blastomeres in each embryo were determined by FISH and compared to evaluate their preimplantation diagnostic potential. Results: Chromosomes (16, 22, X, Y) and (13, 18, 21) were selected on the basis of the high aneuploid prevalence in abortuses for the former group and the presence of trisomy in the newborn for the latter. Thirty-six (72%) of 50 blastomeres gave signals to permit a diagnosis. Diagnoses made from biopsied blasotmeres were consistent with the diagnoses made from the remaining sibling blastomeres in 18 embryos. In only 2 of 20 cases did the biopsied blastomere diagnosis and the embryo diagnosis not match. Conclusions: If FISH of biopsied blastomere was successful, a preimplantation diagnosis could be made with 10% error. When a combination of chromosome-13, -16, -18, -21, -22, -X, and -Y probes was used, up to 65% of the embryos destined to be aborted could be detected.     

Estrogen - and gestagen - receptors in ovarian carcinoma

Estrogen (ER) - and progestagen (PgR) - receptors were estimated by a DCC method using Scatchard plot analysis In tissue samples of 68 patients with ovarian carcinomas. The mean ER and PgR levels were at 52 and 74 fmol/mg cytosol protein, respectively. ER+ PgR+ records were noted in 32.4%, ER+ PgR- in 26.4%, ER- PgR+ in 7.4%, and 33.8% presented with ER- PgR-. In the surviving group 44.1% had Er+ PgR+, whereas the patients who died had an incidence of only 20.5% ER+ PgR+. In addition, the incidences of ER+ PgR+ in stage I plus II and stage III plus IV patients were 42.6 and 29.5%, respectively. Furthermore, higher incidences of ER+ PgR+ were recorded in patients older than 60 years of age (63%) than in younger subjects (36%). The present data combine to suggest that receptor assays should become a useful tool in the management of patients bearing ovarian carcinomas. In addition, ER and PgR determinations provide a prognostic index and may improve the possibility to predict which well-differentiated stage I ovarian carcinomas are likely to recur.     

PKC delta in preeclamptic placentas promotes Bax dissociation from 14-3-3 zeta through 14-3-3 zeta phosphorylation

OBJECTIVE: We investigated placental apoptosis and the expression of and interactions between 14-3-3 and Bcl-2 family proteins during preeclampsia. In addition, we explored the mechanism of Bax dissociation from 14-3-3, hypothesizing that PKC-mediated phosphorylation of 14-3-3 results in dissociation of Bax from 14-3-3 proteins, and leads to apoptosis. METHODS: Placental samples from 10 women with preeclampsia and 10 normotensive control patients were analyzed using M30-specific immunohistochemistry to assess placental apoptosis. Biochemical markers of cellular apoptosis, such as cleaved caspase-3, Bax, Bcl-2, 14-3-3, and PKC were followed by Western blotting. Interaction of 14-3-3 proteins with Bax and with PKC was assessed by immunoprecipitation. RESULTS: M30-positive cells were widespread in the preeclamptic placentas. The levels of cleaved caspase-3, Bax, 14-3-3 zeta, phospho-(Ser)-14-3-3, and PKC delta were significantly higher in the preeclamptic placentas than in normal placentas. Preeclampsia was also associated with weaker interactions between 14-3-3 zeta and Bax and stronger interactions between 14-3-3 zeta and PKC delta. CONCLUSION: Our results suggest that PKC delta in preeclamptic placentas promotes Bax dissociation from 14-3-3 zeta through the phosphorylation of 14-3-3 zeta. This finding may at least in part explain the apoptosis-inducing activity of PKC delta, revealing the important role of PKC delta in the development of apoptosis-related diseases such as preeclampsia.     

14-3-3γ在人卵巢上皮性癌中的表达检测

目的:检测14-3-3γ在卵巢上皮性癌组织的表达,探讨在卵巢上皮性癌发病机理中14-3-3γ蛋白家族的作用机制。方法:应用实时荧光定量PCR方法检测14-3-3γ在15例正常卵巢组织和52例卵巢上皮性癌组织中的表达差异,应用原位杂交方法检测14-3-3γ mRNA在正常卵巢组织和卵巢上皮性癌组织中的定位。结果:实时荧光定量PCR结果经过Mann-Whitney U检验,表明卵巢癌组的14-3-3γ mRNA水平显著高于正常卵巢组。14-3-3γ mRNA定位于卵巢癌细胞中,在正常卵巢组织中没有明显信号出现。结论:在人上皮性卵巢癌中,14-3-3γ转录上调,14-3-3γ mRNA定位于癌细胞。由此推测,14-3-3γ可能参与了人上皮性卵巢癌的发生。